These results suggested that the effect of Rac1 inhibition was not exerted through the p53 pathway activation, suggesting that MM may progress when Rac1 oncogenic activity exceeds the tumor suppressor effect of p53. This evidence concerns the gene RAC1 and Miyoshi myopathy.